Share Name Share Symbol Market Type Share ISIN Share Description
Btg Plc LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 840.00p 839.00p 840.00p - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 620.5 -70.6 3.9 215.4 3,254

Btg Share Discussion Threads

Showing 5101 to 5123 of 6225 messages
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
DateSubjectAuthorDiscuss
24/1/2018
14:26
That should have been £sterling!
fhmktg
24/1/2018
14:25
Rise in the £ knocking the future profits?
fhmktg
23/1/2018
12:38
Major job then!
semper vigilans
20/1/2018
11:51
As expected, the share price is back to where it was. If anything last week was taken as an opportunity to increase holdings
estienne
19/1/2018
11:14
The 2027 patent extension was concerning the delivery of zytiga and to my knowledge filed by Janssen so I don’t know if we would of been entitled to royalties anyway. Looking back long term holders of BTG were fortunate that zytiga was such a great success and in my opinion without the earning stream BTG may not of survived in its present form.
dp1umb
19/1/2018
10:19
Zytiga - 2017 interim report: – No generic entrant expected in the US before October 2018 – No generic entrant expected in Europe before September 2021
retsig
19/1/2018
06:08
Blimey bargainbob, you ARE chirpy this week!!
spyder
19/1/2018
04:08
More likely it will fall more.
bargainbob
18/1/2018
20:53
It recovered its price to end up just over 2% down. I expect it will bounce back tomorrow.
estienne
18/1/2018
18:22
We are the Invincibles, and we are here to serve you better, we are pro in all form of hacks and available for hire, we help in securing company websites, hack any form of social media, we are available for any special project but all hack must come with a reasonable proposal as we don't just accept any hack without a legit or legal reason. You can reach our website to read more and hire us. http://bronxjohn7.wixsite.com/hacking We are invincibles, we keep our words.
invincibles
18/1/2018
18:03
The patent position regarding zytiga has always been hard to decipher, my understanding is that the original patents held by BTG were due to expire this year and BTG have always stated this in there guidance. The confusion is that there have been different patents applied for and issued in the USA that cover the use of Zytiga with the steroid prednisone I might be wrong but I think this is the disputed patent.
dp1umb
18/1/2018
17:45
I guess that the market view is that the ruling won't stick? J&J shares are only down 0.5%. The long term uptrend is still intact - but only just!!
spyder
18/1/2018
17:36
That's years away.There is a short term blip , with more bad news blips than good news blips.
bargainbob
18/1/2018
17:33
BB, Varithena will probably come good.
retsig
18/1/2018
17:29
Another hole in BTG earnings , cannot understand why the share price is holding up. What good news I'am missing.
bargainbob
18/1/2018
15:10
Hard to say but they paid us 70m in the last results . But it will take a while for the generic drugs to get into the market anyway and wont mean that sales will just dry up .
king1pin2
18/1/2018
13:03
so whats the inpact to BTG £20 million a year ?
bargainbob
18/1/2018
10:09
seems to be holding above 710
estienne
18/1/2018
09:45
We wont be the ones that foot that bill tho.
king1pin2
18/1/2018
09:15
'Obviousness' is a very difficult area of patent law.The US Patent office will have a very detailed protocol for dealing with it and the Appeal court will follow that carefully to ensure that there is real substance behind any appeal.Lots of money for expensive lawyers.The US government interest will be to lower health costs.Not going to be sorted out in the short term!
fhmktg
18/1/2018
09:14
what does it mean “ 30 Months ! stay triggered «
a1ord53
18/1/2018
08:56
NEW BRUNSWICK, N.J., Jan. 17, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) issued the following statement regarding today's Inter Partes Reviews regarding ZYTIGA® (abiraterone acetate): "We are disappointed in and strongly disagree with the U.S. Patent and Trademark Office's (USPTO) decisions relating to ZYTIGA® as part of the Inter Partes Reviews. We are evaluating our options with respect to a request for rehearing and/or appeal to the Court of Appeals for the Federal Circuit. We believe the '438 patent is valid and will continue to vigorously defend it." Inter Partes Review decisions by the USPTO do not result in termination of a 30-month stay triggered under the Hatch-Waxman Act by the timely filing of a patent infringement lawsuit against a generic ANDA applicant.
spyder
18/1/2018
08:52
That's a blow for J&J as well as for our cash flow!
fhmktg
Chat Pages: Latest  213  212  211  210  209  208  207  206  205  204  203  202  Older
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191020 05:40:43